WallStreetZenWallStreetZen

NASDAQ: KPRX
Kiora Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for KPRX

Based on 1 analyst offering 12 month price targets for Kiora Pharmaceuticals Inc

Min Forecast
$10.00+383.09%
Avg Forecast
$10.00+383.09%
Max Forecast
$10.00+383.09%

Should I buy or sell KPRX stock?

Based on 1 analyst offering ratings for Kiora Pharmaceuticals Inc.

Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their KPRX stock forecasts and price targets.

KPRX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-09-02

1 of 1

Forecast return on equity

Is KPRX forecast to generate an efficient return?

Company
N/A
Industry
279.01%
Market
232.09%

Forecast return on assets

Is KPRX forecast to generate an efficient return on assets?

Company
N/A
Industry
94.83%

KPRX earnings per share forecast

What is KPRX's earnings per share in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
-$2.58
Avg 2 year Forecast
-$2.40
Avg 3 year Forecast
-$2.10

KPRX revenue forecast

What is KPRX's revenue in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
$1.5M
Avg 2 year Forecast
$765.0k
Avg 3 year Forecast
$0.0

KPRX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
KPRX$2.07$10.00+383.09%Buy
INAB$1.64N/AN/A
ALZN$2.44$42.00+1,621.31%Buy
MTNB$1.18N/AN/A
APRE$1.19N/AN/A
View Top Biotech Stocks

Kiora Pharmaceuticals Stock Forecast FAQ

Is Kiora Pharmaceuticals Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: KPRX) stock is to Buy KPRX stock.

Out of 1 analyst, 0 (0%) are recommending KPRX as a Strong Buy, 1 (100%) are recommending KPRX as a Buy, 0 (0%) are recommending KPRX as a Hold, 0 (0%) are recommending KPRX as a Sell, and 0 (0%) are recommending KPRX as a Strong Sell.

If you're new to stock investing, here's how to buy Kiora Pharmaceuticals stock.

What is KPRX's earnings growth forecast for 2025-2027?

(NASDAQ: KPRX) Kiora Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 47.5%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 43.24%.

Kiora Pharmaceuticals's earnings in 2025 is -$8,542,135.On average, 4 Wall Street analysts forecast KPRX's earnings for 2025 to be -$9,472,522, with the lowest KPRX earnings forecast at -$9,371,378, and the highest KPRX earnings forecast at -$9,461,488. On average, 4 Wall Street analysts forecast KPRX's earnings for 2026 to be -$8,816,010, with the lowest KPRX earnings forecast at -$8,722,591, and the highest KPRX earnings forecast at -$8,804,976.

In 2027, KPRX is forecast to generate -$7,728,077 in earnings, with the lowest earnings forecast at -$7,425,015 and the highest earnings forecast at -$7,955,373.

What is KPRX's revenue growth forecast for 2025-2027?

(NASDAQ: KPRX) Kiora Pharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 104.68%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.51%.

Kiora Pharmaceuticals's revenue in 2025 is $0.On average, 4 Wall Street analysts forecast KPRX's revenue for 2025 to be $5,627,241, with the lowest KPRX revenue forecast at $0, and the highest KPRX revenue forecast at $11,585,495. On average, 4 Wall Street analysts forecast KPRX's revenue for 2026 to be $2,813,620, with the lowest KPRX revenue forecast at $0, and the highest KPRX revenue forecast at $5,792,748.

In 2027, KPRX is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.

What is KPRX's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: KPRX) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 94.83%.

What is KPRX's Price Target?

According to 1 Wall Street analyst that have issued a 1 year KPRX price target, the average KPRX price target is $10.00, with the highest KPRX stock price forecast at $10.00 and the lowest KPRX stock price forecast at $10.00.

The Wall Street analyst predicted that Kiora Pharmaceuticals's share price could reach $10.00 by Sep 2, 2026. The average Kiora Pharmaceuticals stock price prediction forecasts a potential upside of 383.09% from the current KPRX share price of $2.07.

What is KPRX's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: KPRX) Kiora Pharmaceuticals's current Earnings Per Share (EPS) is -$2.20. On average, analysts forecast that KPRX's EPS will be -$2.58 for 2025, with the lowest EPS forecast at -$2.55, and the highest EPS forecast at -$2.57. On average, analysts forecast that KPRX's EPS will be -$2.40 for 2026, with the lowest EPS forecast at -$2.37, and the highest EPS forecast at -$2.39. In 2027, KPRX's EPS is forecast to hit -$2.10 (min: -$2.02, max: -$2.16).

What is KPRX's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: KPRX) forecast ROE is N/A, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.